论文信息 - Response to letter regarding article, "Adherence to third European cooperative acute stroke study 3- to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke".

Response to letter regarding article, "Adherence to third European cooperative acute stroke study 3- to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke".

We thank Drs Sen and Powers1 for their interest in our article.2 Their objective in their letter is “to caution readers that these data should not be interpreted as indicating that patients who do not meet European Cooperative Acute Stroke Study (ECASS) III eligibility criteria benefit from intravenous tissue-type plasminogen activator (tPA) at 3 to 4.5 hours.” We agree that as our data are observational, they do not provide absolute proof of benefit. However, we do feel that these data viewed in combination with other observational studies, and the randomized controlled Third International Stroke Trial (IST-3) suggest that patients with these additional exclusion criteria may benefit from treatment with IV tPA at >3 to 4.5 hours. They state that “ECASS III medical and surgical patients both did better than their counterparts in NINDS… the natural history of …

Eric E. Smith | C. Cronin

[1] W. Powers,et al. Letter by Sen and Powers regarding article, "Adherence to third European cooperative acute stroke study 3- to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke". , 2015, Stroke.

[2] Eric E. Smith,et al. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome: Data From Get With The Guidelines-Stroke , 2014, Stroke.